Performance Evaluation of the NaviCam SB Capsule Endoscope System for the Diagnosis of Small Bowel Diseases

Not Applicable

Completed

• Conditions: Small Bowel Disease
• Interventions: Device: NaviCam SB; Device: PillCam SB3

• Registration Number: NCT05086471
• Lead Sponsor: Wuhan Union Hospital, China

Brief Summary

This study uses a comparative method to evaluate the performance of the NaviCam SB capsule endoscope system in comparison to the PillCam SB3 capsule system for the diagnosis of small bowel diseases.

Detailed Description

This study adopts a prospective and self-controlled design. The subjects are adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding; Subjects swallow two types of SB capsules approximately 40 minutes apart in a randomized order. During the capsule endoscopy, the doctor can view the small bowel images taken by the capsules in real time. This study adopts a method of independent image reading in the participating centers. Two physicians of digestive endoscopy respectively review the images captured by the experimental capsule and the control capsule for normal versus abnormal findings, type of findings and categorization (lesions, polyps, bleeding, etc.), capsule transit time, reading time, and image quality.

Study Timeline

• Study Start: 2021-09-23
• Study First Submitted: 2021-09-30
• Status Verified: 2021-10
• Study First Submitted QC: 2021-10-20
• Study First Posted: 2021-10-21
• Primary Completion: 2021-12-01
• Study Completion: 2021-12-30
• Last Update Submitted: 2023-09-14
• Last Update Posted: 2023-09-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 87

Inclusion Criteria

1. Adult patients (≥18 years old) who have symptoms of small bowel disease or suspected GI bleeding;
2. Those need capsule endoscopy because the recurring GI symptoms cannot be explained by other imaging methods;
3. Those can understand and accept this study protocol and voluntarily sign an informed consent.

Exclusion Criteria

1. Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule;
2. Patient with known gastrointestinal motility disorders;
3. Patient with known or suspected gastrointestinal obstruction, stenosis or fistula;
4. Patient with known or suspected delayed gastric emptying;
5. Patient suffers from any condition, such as swallowing problems, which precludes compliance with study and/or device instructions;
6. Patient has any allergy or other known contraindication or intolerance to the medications used in the study;
7. Patient has any condition, which precludes compliance with study and/or device instructions;
8. Women who are either pregnant or nursing at the time of screening;
9. Concurrent participation in another clinical trial using any investigational drug or device;
10. Patient suffers from a life-threatening condition;
11. Patients with history or clinical evidence of renal disease and/or previous clinically significant laboratory abnormalities of renal function parameters;
12. Patients with pace-maker or implantable cardioverter other implantable electronic medical device;
13. Patient with an easily magnetized metal part;
14. Patient requires endoscopic placement of the capsule;
15. Others considered by the investigator not suitable for this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
NaviCam SB	NaviCam SB	After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.
PillCam SB3	PillCam SB3	After gastrointestinal preparation, the enrolled patients swallow NaviCam SB and the PillCam SB3 capsules approximately 40 minutes apart in a randomized order for small bowel capsule endoscopy.

Primary Outcome Measures

Name	Time	Method
Diagnostic agreement rate	14 days	The diagnosis of subjects by the two types of small bowel capsule endoscopes through independent image reading, that is, the agreement between the two systems with respect to the diagnosis of normal or abnormal subject.

Secondary Outcome Measures

Name	Time	Method
diagnosis rate	14 days	Comparison of the diagnosis rate (examination results within one week before or after enrollment) with other standard mucosal imaging tools (upper GI endoscopy, enteroscopy, colonoscopy, etc.)
Intestinal transit time	14 days	The time from capsule swallowing to capsule excretion
Quality of small bowel images	14 days	Comparison of the quality of small intestine pictures taken with the two capsules
Ease of swallowing the capsule	14 days	The subject's supervisor determines how easy it is to swallow the capsule and which of the following feelings is very easy, easy, moderate, difficult, or very difficult.
Image reading time	14 days	Comparison of the reading times of the two capsules

Trial Locations

Locations (1)

Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology; 🇨🇳 Wuhan, Hubei, China